Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

The prognostic value of CAR-hematox in predicting toxic events in patients with relapsed refractory B cell lymphoma receiving 7x19 CAR-T treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

WQWenbin QianWLWen Lei

Discussion

Loading...

Member takes

Overview

Prognostic model predicts adverse effects and progression-free survival in relapsed/refractory B-cell lymphoma receiving CAR-T therapy.

Key Points

  • This research aims to validate the CAR-HEMATOTOX score for predicting toxicity and survival outcomes in CAR-T treatment.
  • Retrospective analysis of 39 patients with relapsed/refractory B-cell lymphoma
  • Classification of patients into low-risk and high-risk groups based on the HT score
  • Evaluation of incidence and severity of CRS, ICANS, and hematological toxicities
  • Analysis of correlation between HT scores, progression-free survival (PFS), and overall survival (OS)
  • High-risk patients had a significantly higher incidence of grade 3 or higher hematological toxicity (100% vs. 30.77%, p<0.01)
  • The high-risk group showed a higher incidence of grade 3 or greater delayed hematological toxicity (30.77% vs. 15.68%, p<0.01)
  • Survival time was similar across groups, median 19.8+9 months for high-risk patients and median 20.2+10.1 months for low-risk patients
  • 24-month survival rate was 42% in low-risk group versus 15% in high-risk group.

Cite This Study

Qian et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc16https://doi.org/10.1182/blood-2025-7687
View Full Paper
Ask AI
Bookmark
Share